Marburg Hemorrhagic Fever - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Marburg Hemorrhagic Fever - Pipeline Review, H2 2016’, provides an overview of the Marburg Hemorrhagic Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Marburg Hemorrhagic Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marburg Hemorrhagic Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Marburg Hemorrhagic Fever

The report reviews pipeline therapeutics for Marburg Hemorrhagic Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Marburg Hemorrhagic Fever therapeutics and enlists all their major and minor projects

The report assesses Marburg Hemorrhagic Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Marburg Hemorrhagic Fever

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Marburg Hemorrhagic Fever

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Marburg Hemorrhagic Fever pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Arno Therapeutics, Inc.

BioCryst Pharmaceuticals, Inc.

GeoVax Labs, Inc.

GlaxoSmithKline Plc

Integrated BioTherapeutics, Inc.

Johnson & Johnson

NanoViricides, Inc.

Profectus BioSciences, Inc.

Sarepta Therapeutics, Inc.

Arno Therapeutics, Inc.

BioCryst Pharmaceuticals, Inc.

GeoVax Labs, Inc.

GlaxoSmithKline Plc

Integrated BioTherapeutics, Inc.

Johnson & Johnson

NanoViricides, Inc.

Profectus BioSciences, Inc.

Sarepta Therapeutics, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Marburg Hemorrhagic ...

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Marburg Hemorrhagic Fever Overview 8

Therapeutics Development 9

Pipeline Products for Marburg Hemorrhagic Fever - Overview 9

Pipeline Products for Marburg Hemorrhagic Fever - Comparative Analysis 10

Marburg Hemorrhagic Fever - Therapeutics under Development by Companies 11

Marburg Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes 12

Marburg Hemorrhagic Fever - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Marburg Hemorrhagic Fever - Products under Development by Companies 16

Marburg Hemorrhagic Fever - Products under Investigation by Universities/Institutes 17

Marburg Hemorrhagic Fever - Companies Involved in Therapeutics Development 18

Arno Therapeutics, Inc. 18

BioCryst Pharmaceuticals, Inc. 19

GeoVax Labs, Inc. 20

GlaxoSmithKline Plc 21

Integrated BioTherapeutics, Inc. 22

Johnson & Johnson 23

NanoViricides, Inc. 24

Profectus BioSciences, Inc. 25

Sarepta Therapeutics, Inc. 26

Marburg Hemorrhagic Fever - Therapeutics Assessment 27

Assessment by Monotherapy Products 27

Assessment by Combination Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

(Ebola + Marburg) (monovalent) vaccine - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

(Ebola + Marburg) (trivalent) vaccine - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

(Ebola + Marburg) vaccine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

(Ebola [Sudan, Zaire] + Marburg) vaccine - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

1-E703 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Antibodies for Ebola and Marburg Viral Infections - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

AR-12 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ARD-5 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

AVI-7288 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

BCX-4430 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

FDX-000 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

GOVXE-301 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

GOVXE-302 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

imatinib mesylate - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Marburg vaccine - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Monoclonal Antibody for Marburg Virus - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Monoclonal Antibody to Inhibit Glycoprotein for Ebola and Marburg Infections - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

nilotinib - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Small Molecule for Ebola and Marburg Infections - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecules for Ebola and Marburg Infections - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Marburg Hemorrhagic Fever - Dormant Projects 70

Marburg Hemorrhagic Fever - Discontinued Products 71

Marburg Hemorrhagic Fever - Product Development Milestones 72

Featured News & Press Releases 72

Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform 72

Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate 73

Sep 17, 2013: BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases to Develop BCX4430 for the Treatment of Marburg Virus Disease 73

May 07, 2013: Sarepta Therapeutics Initiates Dosing In Phase I Multiple Ascending Dose Study Of Drug For Treatment Of Marburg Virus 74

Mar 04, 2013: Sarepta Therapeutics's Marburg Drug Shows High Survival Rates After Intramuscular Delivery In Non-Human Primates 74

Appendix 76

Methodology 76

Coverage 76

Secondary Research 76

Primary Research 76

Expert Panel Validation 76

Contact Us 76

Disclaimer 77

List of Tables

List of Tables

Number of Products under Development for Marburg Hemorrhagic Fever, H2 2016 9

Number of Products under Development for Marburg Hemorrhagic Fever - ...

List of Tables

Number of Products under Development for Marburg Hemorrhagic Fever, H2 2016 9

Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Marburg Hemorrhagic Fever - Pipeline by Arno Therapeutics, Inc., H2 2016 18

Marburg Hemorrhagic Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2016 19

Marburg Hemorrhagic Fever - Pipeline by GeoVax Labs, Inc., H2 2016 20

Marburg Hemorrhagic Fever - Pipeline by GlaxoSmithKline Plc, H2 2016 21

Marburg Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H2 2016 22

Marburg Hemorrhagic Fever - Pipeline by Johnson & Johnson, H2 2016 23

Marburg Hemorrhagic Fever - Pipeline by NanoViricides, Inc., H2 2016 24

Marburg Hemorrhagic Fever - Pipeline by Profectus BioSciences, Inc., H2 2016 25

Marburg Hemorrhagic Fever - Pipeline by Sarepta Therapeutics, Inc., H2 2016 26

Assessment by Monotherapy Products, H2 2016 27

Assessment by Combination Products, H2 2016 28

Number of Products by Stage and Target, H2 2016 30

Number of Products by Stage and Mechanism of Action, H2 2016 32

Number of Products by Stage and Route of Administration, H2 2016 34

Number of Products by Stage and Molecule Type, H2 2016 36

Marburg Hemorrhagic Fever - Dormant Projects, H2 2016 70

Marburg Hemorrhagic Fever - Discontinued Products, H2 2016 71

List of Figures

List of Figures

Number of Products under Development for Marburg Hemorrhagic Fever, H2 2016 9

Number of Products under Development for Marburg Hemorrhagic Fever - ...

List of Figures

Number of Products under Development for Marburg Hemorrhagic Fever, H2 2016 9

Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 27

Assessment by Combination Products, H2 2016 28

Number of Products by Top 10 Targets, H2 2016 29

Number of Products by Stage and Top 10 Targets, H2 2016 29

Number of Products by Top 10 Mechanism of Actions, H2 2016 31

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 31

Number of Products by Routes of Administration, H2 2016 33

Number of Products by Stage and Routes of Administration, H2 2016 33

Number of Products by Molecule Types, H2 2016 35

Number of Products by Stage and Molecule Types, H2 2016 35

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports